COSCIENS Biopharma Inc

CSCI NPV
Create an alert
Sell
8.60 CAD
Buy
8.87 CAD
0.18 CAD (2.05%)
Last updated today at
Back to dashboard

Company Information

About this company

COSCIENS Biopharma Inc. is a Canada-based holding company. The Company is operating through its subsidiaries, including Ceapro Inc. (Ceapro) and Nualtis. Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro's primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries. Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing.

Key people

Peter H. Puccetti
Chairman of the Board, President, Chief Executive Officer
David Spear
Director
Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Michel Regnier
Senior Vice President, Chief Technology Officer
Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Anthony J. Giovinazzo
Director
Ulrich Kosciessa
Director
Ronald W. Miller
Director
Robert A. Seager
Director
Click to see more

Key facts

  • Shares in issue
    1.06m
  • EPIC
    CSCI
  • ISIN
    CA22112H2000
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    CA$9.72m
  • Employees
    28
  • Exchange
    Toronto Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.